XML 44 R33.htm IDEA: XBRL DOCUMENT v3.23.3
Collaboration Agreements - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Feb. 28, 2023
May 31, 2022
Dec. 11, 2020
Aug. 31, 2017
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2020
Dec. 31, 2022
Jan. 14, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Loss from G42 Promissory Note early redemption             $ 313,000 $ 0      
Contract liabilities, net of current portion         $ 18,669,000   18,669,000     $ 18,669,000  
Revenue         0 $ 0 0 2,009,000      
G42 Investments                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Shares sold (in shares)   10,386,274                  
Sale of stock, price per share (in usd per shares)   $ 2.41                  
Sale of stock, consideration received on transaction, gross   $ 25,000,000                  
Sale of stock, consideration received on transaction   12,500,000                  
Accounts and financing receivable, after allowance for credit loss   12,500,000                  
Proceeds from collection of notes receivable $ 12,000,000                    
Discount rate 3.75%                    
Loss from G42 Promissory Note early redemption $ 300,000                    
G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement | G42 Investments                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Sale of stock, consideration received on transaction, gross   25,000,000                  
Accounts and financing receivable, after allowance for credit loss   12,500,000                  
Proceeds from collection of notes receivable $ 12,000,000                    
Discount rate 3.75%                    
Loss from G42 Promissory Note early redemption $ 300,000                    
Collaborative arrangement, contingent consideration   30,000,000                  
Collaborate arrangement, contingent consideration transferred, cash   30,000,000                  
Contract liabilities, net of current portion         18,700,000   18,700,000        
Discount on note receivable             600,000        
Collaboration revenue recognized         0   0        
Revenue         0   0        
Receivables, fair value disclosure         11,900,000   11,900,000        
G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement | G42 Investments | Class A Common Stock                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Common stock, value   $ 5,700,000                  
Share price (in usd per share)   $ 0.55                  
G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement | Cogna                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Royalties receivable, period   10 years                  
Collaborative Arrangements | JDRF                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Maximum funding percentage of research and development milestones       50.00%              
Collaborative Arrangements | JDRF | Phase 2 MRCT | License and Technology Transfer Services of Chemistry and Manufacturing Know-How                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Adjustments to transaction price for performance obligations             0 0      
Collaborative Arrangements | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 2 MRCT                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Maximum contribution amount to clinical trial                     $ 3,000,000
Potential development and regulatory milestone payments                     $ 3,000,000
Collaborative Arrangements | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 2 MRCT | License and Technology Transfer Services of Chemistry and Manufacturing Know-How                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Adjustments to transaction price for performance obligations             0 2,000,000      
Collaborative Arrangements | Anteris Bio Inc                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Potential development and regulatory milestone payments     $ 151,000,000                
License Fee Received     $ 2,000,000                
Contract with customer, liability, revenue recognized         $ 0 $ 0 $ 0 $ 0      
Collaborative Arrangements | Anteris Bio Inc | License and Technology Transfer Services of Chemistry and Manufacturing Know-How                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
License Fee Received                 $ 2,000,000    
Equity interest received                 $ 4,200,000